Study dispels long held myth that Testosterone Replacement Treatment raises risk of prostate cancer.

The findings of a two year study published online in the Journal Of Sexual Medicine*** by members of the Society for the Study of Androgen Deficiency (Andropause Society) has firmly ruled out a long held belief that Testosterone Replacement Therapy (TRT) used to treat Testosterone Deficiency Syndrome (Hypogonadism, Andropause) may increase a patients chance of developing Prostate Cancer.

Testosterone Deficiency Syndrome (Hypogonadism, Andropause), is a serious condition characterised by depression, weight gain, brain fog, memory loss, irritability, night sweats, decreased sex drive, erection problems, loss of energy and is associated with heart failure, diabetes, obesity and osteoporosis. The condition is estimated to affect 2 million men over 50* and an undetermined number of younger males. *

Commenting on the outcome of the research by Society for the Study of Androgen Deficiency (Andropause Society) trustee, Dr Mark Feneley and the charity's President Dr Malcolm Carruthers, conducted with 1500 patients, the organisation's voluntary chief executive Paul Pennington said, "It is gratifying to know we can finally remove one of the obstacles that has seemingly prevented the medical profession from treating this common hormonal disturbance in men, which can wreck their lives, loves and health."

He added, "The experience of clinicians working in this important area of men's health has shown that rather than being dangerous, carefully regulated and monitored TRT has been shown to be remarkably safe. This is backed by recent studies showing the medical benefits of testosterone treatment as emphasised by Professor Tom Trinick, from the Department of Chemical Pathology at The Ulster Hospital Belfast and former chairman of the Society for the Study of Androgen Deficiency, that highlight the benefits of TRT. Evidence shows it reduces obesity, can prevent complications of diabetes, lowers cholesterol and is being used to prevent heart attacks and strokes in diabetics."

**Trinick T.R.,Feneley M.R. Welford H, Carruthers M. Department of Chemical Pathology The Ulster Hospital Belfast, Institute of Urology & Nephrology University College Hospital London, Centre for Men's Health, The Aging Male 2010 1-6 *International web survey shows high prevalence of symptomatic testosterone deficiency in men. July 2010 Informa healthcare.

***The Journal of Sexual Medicine is the Official Journal of the International Society for Sexual Medicine (ISSM). The International Society for Sexual Medicine was founded in 1982 for the purpose of promoting research and exchange of knowledge for the clinical entity 'impotence' throughout the international scientific community. The principal orientation of ISSM was initially towards basic science of erection, defects in the erectile mechanism, and the clinical aspects of diagnosis and treatment of erectile dysfunction. The focus is now towards the whole field of sexual medicine.


top of page

The Hugh Welford Memorial library